Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.

Goal 3: Advance Translational Research

Submitted by (@njkenyon)

Using "omics" technologies to define responders to drug therapies

Metabolomic and proteomic technologies open tremendous avenues to define at the systemic level and, in the case of the lung, the organ level response to drug and non-drug interventions. The concept of responders and non-responders to therapies is poorly defined and hampers development of biomarkers and appropriate animal models. Omics technologies can bridge these important areas. In lung disease, breath analysis could ...more »

Voting

7 net votes
13 up votes
6 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@davidcormode)

Translation of novel computed tomography technologies

Computed tomography and related x-ray imaging techniques are mainstays of cardiovascular imaging and treatment. Novel technologies are emerging for CT that promise further improvements for cardiovascular disease, such as spectral CT, phase contrast CT or nanoparticle contrast agents. However, many challenges remain for their translation to patients.

Voting

-9 net votes
3 up votes
12 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@teresabarnes)

The Future of Fibrosis Research

A critical challenge in the area of fibrosis research (including heart, lung and other organs) is the absence of a central system to act as air traffic control for progress, innovations and gaps in the science. Like the area of cancer research was 30 years ago, the fibrosis research area is fragmented and disconnected. The answer in the cancer effort to creating a centralized, focused system was with the National Cancer ...more »

Voting

3 net votes
6 up votes
3 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@rao000)

Advancing translational research requires timely in-depth analysis of large datasets

1. NHLBI investments over the last decade in terms of genomic approaches have yielded many research findings. 2. Rapid analyses of early data identified the "low hanging" fruit (and perhaps some/many important results were missed); this limited the scope of translation (partly because of relatively limited discovery?) 3. Important data are being generated at much greater rate than the data are processed/analyzed thoughtfully. ...more »

Voting

1 net vote
11 up votes
10 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Developing a Research Community for T4 Translation Research

What incentives will encourage current and new NHLBI investigators to pursue late translation (T4) research of proven effective interventions in heart, lung, blood, and sleep diseases? One of NHLBI’s current strategic plan’s goals is to translate discovery and early translation research knowledge to late stage T4 translation for use in populations so that it has significant positive health impacts and provides a return ...more »

Voting

-3 net votes
8 up votes
11 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@rlevine)

The need for funding priorities and emphasis on valve disease and large-animal preclinical studies

Investigators need NHLBI support for programs that transform our approach to heart valve disease to mechanism-based prevention with large-animal preclinical studies through: an NHLBI-sponsored sponsored Heart Valve Network; development of models of genetic and acquired valve disease; a study section devoted to valve disease; and RFAs and RFPs based on Task Force priorities in mitral valve disease.

Voting

2 net votes
4 up votes
2 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@wheeze)

Clinical Trial Methodology

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan:

 

Are the current methodologies for clinical trials still the best practices for conducting efficient clinical trials?

Voting

2 net votes
15 up votes
13 down votes
Active